Advanced Er Her2 Breast Cancer clinical trials

Explore recruiting advanced er her2 breast cancer clinical trials.

Recruiting advanced er her2 breast cancer studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Advanced Er Her2 Breast Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 1, First-in-Human Study of MEN2312, a KAT6 inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer

Spain

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Advanced Er Her2 Breast Cancer trials by city

Advanced Er Her2 Breast Cancer clinical trials

Recruiting advanced er her2 breast cancer studies right now

Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer

Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors

PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

Phase Ib/II Clinical Study of QLS1304 Combined With Endocrine Therapy in the Treatment of ER+/HER2- Breast Cancer Patients

Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

Study of PF-07248144 in Advanced or Metastatic Solid Tumors

Efficacy and Safety of Ribociclib Combined With AI Versus Physician&Amp;#39;s Choice of Chemotherapy Sequential Endocrine Therapy in ER Middle-low-expression/HER2-negative Advanced Breast Cancer (Rachel)

Also recruiting in Europe

A Phase 1, First-in-Human Study of MEN2312, a KAT6 inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer

Advanced Er Her2 Breast Cancer trials by city

Other conditions